A rapid colorimetric assay was described by Mosmann (1983) for determining the ability of viable cells to convert a soluble tetrazolium salt, 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), into an insoluble formazan precipitate. The MTT assay is a rapid and quantitative colorimetric system for the determination of the chemosensitivity of tumour cell lines (Carmichael et al., 1987; Park et al., 1987; Schroyens et al., 1990) , and also in fresh leukaemia cells (Twentyman et al., 1989; Pieters et al., 1989; Hanson et al., 1991) . However, the use of this assay for solid tumour tissues has been limited because of contamination by nonmalignant cells in tumour specimens (Kaspers et al., 1991; Campling et al., 1991; Suto, 1991) . Thus, when the MTT assay is employed for chemosensitivity testing of tumour samples, highly purified fresh tumour cells should be used, because contamination by nonmalignant cells affects the results of this assay (Yamaue et al., 1991; Campling et al., 1991; Suto, 1991) .
The present study was designed to determine the chemosensitivity in fresh human gastric cancer, using highly purified tumour cells, and the correlation of this sensitivity with clinical response.
Patients and methods
Fifty-eight patients with gastric cancer were entered in this study. Tumour None of these patients had received any previous antitumour drugs.
Antitumour drugs The antitumour drugs tested were cisplatin (CDDP), etoposide (VP-16), mitomycin C (MMC), doxorubicin (DOX), and 5-fluorouracil (5-FU). Each drug was diluted in complete medium at therapeutic peak plasma concentration (Cmax x 1) achieved by intravenous administration of clinical doses (Scheithauer et al., 1986) . The values were: MMC 1.0 jg ml-'; 5-FU IOLgml-'; DOX 0.4figml-'; CDDP 2.0 Lg ml-'; and VP-16 10tggml , and 10-fold equivalents were also prepared (Cmax x 10). The complete medium used consisted of RPMI-1640 (Nissui Co., Tokyo, Japan) supplemented with 10% heat-inactivated foetal calf serum (GIBCO, New York, USA), 2 mM L-glutamine, and antibiotics (100 U penicillin ml' and 100 fig streptomycin ml-').
Purification offresh human gastric cancer cells
Malignant ascites was immediately centrifuged at 400 g for 5 min and then suspended in complete medium. Freshly excised tumour tissues were processed using enzymatic digestion, as previously described (Yamaue et al., 1990a) . Briefly, tumour tissues were dissected into pieces smaller than 2 mm3 which were immersed in complete medium containing collagenase (2 mg ml-', type V-S; Sigma), hyaluronidase (10 units ml-,, type IV-S; Sigma), and DNase-I (0.4 mg ml-'; Sigma).
After 40 min incubation at 37°C, the cells were harvested, washed, and suspended in complete medium.
The purification of autologous tumour cells has also been previously described (Yamaue et al., 1990b; 1991 (Mosmann, 1983; Yamaue et al., 1991 were used as controls for cell viability, and three wells containing only complete medium were used as controls for nonspecific dye reduction. After incubation, the plates were centrifuged, the supernatants were removed, and 301l/well of MTT solution with 10 lIM of sodium succinate was added to all the wells. The plates were incubated for an additional 4 h, and 150 ll of dimethyl sulfoxide (DMSO) was then added to all the wells (Carmichael et al., 1987) ; the mixtures were pipetted thoroughly to dissolve the dark blue crystals. The plates were then read on a microplate reader (Corona Electric, MTP-32) using a test wavelength of 570 nm and a reference wavelength of 630 nm. The control wells without tumour cells had an OD of less than 0.005, and the samples in which the OD was over 0.1 were accepted for the assay.
The inhibition rate was calculated as follows:
The background of tumour cells (including dead cells) without addition of MTT had an OD of less than 0.012 after 96 h incubation, and the influence of dead tumour cells could therefore be ignored in the present study. The viability of tumour cells was maintained at 75-90% during the 96 h incubation, and the OD570 values before and after 96 h incubation were 0.36 ± 0.17, and 0.33 ± 0.14, respectively.
Chemotherapy on the basis of the results of the MTT assay Twenty of the 51 patients whose tumour cells could be assayed had evaluable lesions. These patients received cancer chemotherapy on the basis of the results of the MTT assay. Two or three drugs were administered, of which inhibition rates were generally more than 50% at ten times the peak plasma concentration. As shown in Figure 1 , there were no significant differences between the chemosensitivity of the well differentiated and the poorly differentiated type at drug concentrations of Cmax x 10 and Cmax x 1. However, the inhibition rates were slightly higher for the poorly differentiated tissues than for the well differentiated tissues when exposed to MMC, DOX, and 5-FU at Cmax x 10, and DOX and 5-FU at Cmax x 1 (0.05 < P < 0.1) (Figure 1 (Table III) . (Table V) .
Discussion
The MTT assay for chemosensitivity testing is a rapid and semi-automated quantitative assay for screening the effects of anticancer drugs on fresh tumour samples (Twentyman et al., 1989; Wilson et al., 1990; Yamaue et al., 1991) , as well as on established cell lines (Twentyman et al., 1987; Carmichael et al., 1987; Park et al., 1987) . However, contamination by non-malignant cells in tumour tissues influences the results of this assay, although the nonmalignant cells are less sensitive to anticancer drugs than the malignant cells (Maehara et al., 1989; Yamaue et al., 1991; Kaspers et al., 1991) . To use this assay for leukaemic cells in peripheral blood or bone marrow, the cells must be enriched to more than 90% by centrifugation with 100% Ficoll-Hypaque alone (Sargent & Taylor, 1989) . The MTT assay has been performed using malignant cells from solid tumour samples, including lung cancer (Campling et al., 1991) and ovarian cancer (Wilson et al., 1990 ) prepared with 100% Ficoll-Hypaque alone, or using malignant cells from gastrointestinal cancer tissues prepared by enzymatic digestion alone (Yamauchi et al., 1991) . The purity of malignant cells from ovarian cancer has been reported to be relatively high; i.e. 70-80% (Wilson et al., 1990) , however, there is marked contamination by nonmalignant cells in gastric cancer tissues as shown in the present study.
Thus, the MTT assay should be performed with highly purified tumour cells in gastric cancer, since the chemosensitivity of malignant tumour cells is distinct from that of non-malignant cells, and moreover, since the chemosensitivity of highly purified tumour cells is also distinct from that of non-purified cells merely separated from tumour tissues (Yamaue et al., 1991) .
Gastrointestinal cancer is more resistant to anticancer drugs than leukaemia and malignant lymphoma (Yamauchi et al., 1991) , and gastric adenocarcinoma is less sensitive to these drugs than lung adenocarcinoma (Kohnoe et al., 1991) . In the present study, the inhibition rates of fresh human gastric cancer cells with CDDP, MMC, DOX, and 5-FU were 66.1%, 63.1%, 54.9%, and 49.0%, respectively, whereas they were 57.9%, 49.3%, 40.6% and 26.4% in a study by Kohnoe et al. (1991) . The effective rates for CDDP, VP-16, MMC, and DOX were 45.5%, 10.0%, 66.7% and 41.7%, respectively (Ohyama et al., 1991) (all data at Cmax x 10). The differences in these findings may be related to the purification of the tumour cells. While Maehara et al. (1987) found that the inhibition rates on the MTT assay were remarkably high for poorly differentiated gastric cancer tissues, exposed to CDDP, MMC, DOX, and 5-FU, compared with those for well differentiated tissues. We found no significant differences between the chemosensitivity of these two types of gastric cancer tissues. The absorbance Another problem associated with the clinical application of the MTT assay is the determination of optimal conditions for the evaluation of chemosensitivity and drug concentration. Camling et al. (1991) and Schroyens et al. (1990) reported that the data for the MTT assay in established cell lines should be expressed as the area under the dose response curves (AUC); however, the usefulness of the MTT assay in clinical samples may be of limited value, since adequate numbers of tumour cells, to enable the assessment of the AUC for several drugs, cannot always be obtained in all cases. Therefore, we used two drug concentrations, including Cmax x 10 and Cmax x 1, for the MTT assay of clinical samples; however, Cmax levels of drugs will vary according to the method of measurement, the clinical protocol, and the individual patient. Many other factors are also involved in drug activity, including alterations to drug metabolites.
In chemosensitive leukaemia, since the lethal concentration to 50% of the cells (LDm) in the dose-response curve was found to be equivalent to Cmax x 1, drugs induced 50% cytotoxicity were considered to be effective at Cmax x 1 (Kaspers et al., 1991) . In an MTT assay for ovarian cancer, Wilson et al. (1990) employed the criteria used for predicting in vivo sensitivity in haematological malignancy, in which the drug concentration was equivalent to Cmax x 2 (Weisenthal et al., 1986) . On the other hand, in human colo-rectal carcinoma cell lines, the AUC which produced 50% growth inhibition was within a clinically achievable range (Cmax x 1) only for 5-FU (Park et al., 1987) , and Cmax x 10-100 was required to reduce 50% of the AUC for other drugs, including CDDP, VP-16, MMC and DOX. These findings are supported by our results that the inhibition rates of 5-FU were 49.0% at Cmax x 10, and 33.1% at Cmax x 1, and that the difference between Cmax x 10 and Cmax x 1 was minimal. In fresh human gastrointestinal cancer, the concentra- tion of drugs used in the MTT assay has usually been Cmax x 10 (Maehara et al., 1987; Yamaue et al., 1991; Ohyama et al., 1991) . In the present study, the inhibition rates obtained with anticancer drugs ranged from 11.6%
(VP-16) to 33.1% (5-FU) at Cmax x 1, and the evaluation could be performed. Therefore, the results obtained at Cmax x 1 should be considered to be clinically applicable. In retrospective studies, the MTT assay has accurately predicted the initial response to chemotherapy in acute leukaemia (Sargent & Taylor, 1989; Santini et al., 1989) , as well as the long-term clinical outcome . The present study was prospective, being designed to determine chemotherapy according to the results of the MTT assay. Clinical response rate was obtained in 12 of the 20 patients (60.0%). We consider this rate to be relatively high, since the response rate for conventional chemotherapy in gastric cancer in our hospital was only 15.9% (Yamaue et al., 1990c) . However, a prospective randomised-controlled study with an adequate number of patients is required for the evaluation of whether the results of the MTT assay in vitro correlate with the clinical response in vivo.
Our investigations continue, by a randomised-controlled prospective study with adequate number of patients, to examine whether the results of the MTT assay using highly purified fresh human tumour cells correlate with clinical response, and further, which drug concentrations should be used in the MTT assay.
